COVID-19 and Fungal Diseases

Coronavirus Disease-2019 (COVID-19) can cause secondary bacterial and fungal infections by affecting the expression of pro-inflammatory markers, such as tumor necrosis alpha and certain cytokines, as well as the numbers of CD<sub>4</sub> and CD<sub>8</sub> cells. In particula...

Full description

Saved in:
Bibliographic Details
Main Authors: Kyoung-Ho Oh (Author), Seung-Hoon Lee (Author)
Format: Book
Published: MDPI AG, 2022-06-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_741531b6d94e4732a5eb0b944f604ef1
042 |a dc 
100 1 0 |a Kyoung-Ho Oh  |e author 
700 1 0 |a Seung-Hoon Lee  |e author 
245 0 0 |a COVID-19 and Fungal Diseases 
260 |b MDPI AG,   |c 2022-06-01T00:00:00Z. 
500 |a 10.3390/antibiotics11060803 
500 |a 2079-6382 
520 |a Coronavirus Disease-2019 (COVID-19) can cause secondary bacterial and fungal infections by affecting the expression of pro-inflammatory markers, such as tumor necrosis alpha and certain cytokines, as well as the numbers of CD<sub>4</sub> and CD<sub>8</sub> cells. In particular, in the head and neck, various fungal species are naturally present, making it the main route of secondary infection. It is difficult to clearly distinguish whether secondary infection is caused by COVID-19 directly or indirectly as a result of the immunocompromised state induced by drugs used to treat the disease. However, the risk of fungal infection is high in patients with severe COVID-19, and lymphopenia is observed in most patients with the disease. Patients with COVID-19 who are immunosuppressed or have other pre-existing comorbidities are at a significantly higher risk of acquiring invasive fungal infections. In order to reduce morbidity and mortality in these patients, early diagnosis is required, and treatment with systemic antifungal drugs or surgical necrotic tissue resection is essential. Therefore, this review aimed to examine the risk of fungal infection in the head and neck of patients with COVID-19 and provide information that could reduce the risk of mortality. 
546 |a EN 
690 |a antifungal therapy 
690 |a COVID-19 
690 |a fungal infection 
690 |a fungi 
690 |a immunosuppressants 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antibiotics, Vol 11, Iss 6, p 803 (2022) 
787 0 |n https://www.mdpi.com/2079-6382/11/6/803 
787 0 |n https://doaj.org/toc/2079-6382 
856 4 1 |u https://doaj.org/article/741531b6d94e4732a5eb0b944f604ef1  |z Connect to this object online.